HeartSciences Inc. (HSCS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Company: HeartSciences Inc. (formerly Heart Test Laboratories, Inc.)
Reporting Period: Quarter ended October 31, 2024 (Fiscal Q2 2025)
Business Model: Medical technology company developing AI-based electrocardiograph (ECG) solutions, specifically the MyoVista wav ECG device and the MyoVista Insights Cloud Platform. The company is pre-revenue in the U.S. market pending FDA clearance.
Recent Corporate Actions: Changed corporate name to HeartSciences Inc. in October 2024; completed a 1-for-100 reverse stock split in May 2024 to regain Nasdaq compliance.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $3,900 |
| Net Loss | $(2,082,918) | $(4,134,607) | $(3,115,233) |
| Operating Expenses | $1,985,033 | $4,060,700 | $2,902,978 |
| Cash & Equivalents (Oct 31, 2024) | $4,052,120 | ||
| Total Debt (Current + Long-Term) | ~$2.42 million (Notes Payable) | ||
| Working Capital | $2,386,368 |
Material Changes vs. Prior Period
- Revenue: No revenue recognized in Q2 2025 or YTD 2025, compared to nominal revenue ($3,900) in the prior year periods. The company remains pre-commercial in the U.S.
- Net Loss: Net loss increased by 19% on a YTD basis ($4.1M vs. $3.1M) and 19% on a quarterly basis ($2.1M vs. $1.7M).
- Operating Expenses: Research and Development (R&D) expenses increased significantly by 83% YTD ($2.4M vs. $1.3M) due to consulting costs for the cloud platform and headcount increases for FDA submission preparation. SG&A expenses remained relatively flat YTD.
- Liquidity: Cash balance decreased by $1.76 million YTD due to operating burn, partially offset by financing activities.
- Debt Structure: In September 2024, the company issued a new $2.51 million unsecured promissory note (Streeterville Note) with net proceeds of ~$1.9 million. The maturity of the existing FRV Note was extended to September 2025.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash resources are deemed insufficient to fund operations for the next 12 months without additional financing.
- Regulatory Path: The company is preparing a 510(k) FDA submission for the MyoVista wav ECG device, targeting the first calendar quarter of 2025. A submission for the MyoVista Insights Cloud Platform is targeted for the second half of 2025.
- Capital Needs: The company plans to raise additional capital through equity sales (via Equity Line and ATM Facility), debt, or strategic partnerships. No assurance is given that such financing will be available.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, citing lack of proper approval processes, insufficient accounting resources, and inadequate segregation of duties.
- Risks: Key risks include failure to obtain FDA clearance, inability to secure additional funding, and potential delisting if Nasdaq compliance is not maintained.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.05 million cash balance against the stated burn rate and the timeline for the Q1 2025 FDA submission.
- Debt Covenants: Review the terms of the Streeterville Note (8.5% interest, 18-month maturity) and the FRV Note (extended to 2025) for potential default triggers or dilutive conversion features.
- Equity Dilution: Monitor the utilization of the $15M Equity Line and $15M ATM Facility, noting that significant share issuance has already occurred to maintain Nasdaq listing.
- Internal Controls: Assess the remediation plan for the disclosed material weaknesses in financial reporting controls.
- Regulatory Milestones: Track the actual submission date of the 510(k) application in Q1 2025 and any FDA feedback received.